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Purpose: Difficulty exists in interpreting the significance of atypical urine cytology. 
This study was performed to assess the diagnostic utility of nuclear matrix protein-22 
(NMP-22) testing when atypical cells are detected during urine cytology.
Materials and Methods: Among patients whose urine cytology was reported as atypical 
between January 2004 and December 2009, a total of 275 who also underwent NMP-22 
testing were enrolled in the present study. These patients were further divided into 
the screening group (143 patients examined as outpatients for hematuria) and the fol-
low-up group (132 patients followed up for previously diagnosed bladder cancer). The 
sensitivity, specificity, positive and negative predictive values, and accuracy were as-
sessed for atypical cytology alone and in conjunction with NMP-22.
Results: Of the 275 patients exhibiting atypical urine cytology, cancer was confirmed 
in 85, yielding a positive predictive value of 30.9% (85/275). Of the 96 patients testing 
positive for NMP-22, 58 were diagnosed with bladder cancer. The positive predictive 
value in conjunction with NMP-22 was 60.4% (58/96). The sensitivity, specificity, neg-
ative predictive value, and accuracy were 68.2% (58/85), 80.0% (152/190), 84.9% 
(152/179), and 76.2% (210/275), respectively. Testing for NMP-22 in the screening and 
follow-up groups increased the positive predictive value from 30.0% (43/143) to 64.0% 
(32/50) and from 31.3% (42/132) to 56.5% (26/46), respectively; there was no significant 
difference between the screening and follow-up groups (p=0.106).
Conclusions: When only cases with atypical urine cytology were examined, NMP-22 
testing increased the detection rate of bladder cancer regardless of whether the test 
was used in screening hematuria or in following up patients.
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INTRODUCTION
In urine cytology, atypical cells are defined as those that 
are beyond the limits of description for normal cells but that 
do not quite fit the description of cancerous cells. Farrow 
et al reported a positive diagnostic rate of 57% in high-risk 
patients with atypical urine cytology [1], and Melamed et 
al reported a positive diagnostic rate of 39% [2]. Thus, the 
identification of atypical cells on urine cytology does not 
rule out cancer.
Atypical cells can be found in normal bladder patients di-
agnosed with cystitis, benign prostatic hyperplasia (BPH), 
or urinary stones, as well as in those undergoing radio-
therapy. Atypical findings in bladder cancer are due to ne-
crotic cancer tissue, high mitotic cancers, and the coex-
istence of inflammation or hematuria [3].
The presence of atypical cells is often encountered during 
the assessment of hematuria and in patients with a history 
of bladder cancer; such a finding usually presents a di-
lemma to the clinician. In the case of atypical urine cytol-
ogy, options for clinical evaluation may include repeated 
cytology, cystoscopy, and surveillance. However, an in-
vasive examination in all patients with hematuria may 
place a substantial burden on both the patient and the Korean J Urol 2011;52:603-606
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TABLE 1. Overall results in patients with the NMP22 
BladderCheck test and atypical cytology and in patients with 
atypical urine cytology only
NMP22BC with 
atypical cytology
Atypical 
cytology only p-value
Positive Negative Positive Negative
Bladder
  cancer (+)
Bladder
  cancer (−)
58
38
  27
152
  85
190
   450
1,423
PPV 60.4% (58/96) 30.9% (85/275) ＜0.001
NMP-22: unclear matrix protein-22, PPV: positive predictive value
physician. Therefore, we considered methods to comple-
ment urine cytology without the use of more invasive 
methods.  
Noninvasive methods include molecular markers, nuclear 
matrix protein-22 (NMP-22), bladder tumor antigen, and te-
lomerase, among others [4,5]. Of these, tests for NMP-22 
yield a positive predictive value (PPV) of 92% in hematuria 
patients, are easy to perform, and are inexpensive [6]. 
Due to these perceived advantages of NMP22, its utility 
in bladder cancer workup had been investigated in the past. 
However, few studies have examined its usefulness in the 
presence of atypical urine cytology. Accordingly, the pres-
ent study aimed to examine the effect of NMP-22 testing 
on the detection rate of bladder cancer in patients with 
atypical urine cytology.
MATERIALS AND METHODS
The study group consisted of 275 consecutive patients with 
urine samples collected between January 2004 and 
December 2009 that had been categorized as atypical be-
cause of the presence of either cell clusters or cytologic 
atypia. These patients had all undergone NMP-22 testing 
after the observation of atypia in urine cytology. Patients 
who did not undergo follow-up after their first diagnosis of 
cytologic atypia were excluded. Of the patients, all of those 
being followed up for bladder cancer had undergone cysto-
scopy, whereas not all of the patients who were being eval-
uated for hematuria had undergone cystoscopy. Patients 
in whom bladder cancer was diagnosed within 1 year after 
the observation of atypical cytology were considered can-
cer-positive.
Of the experimental groups in the present study, the first 
group, the screening group, consisted of subjects with an 
initial presentation of hematuria. This group included pa-
tients with gross or microscopic hematuria and excluded 
all patients undergoing follow-up for bladder cancer. The 
second group, the follow-up group, consisted of patients 
previously pathologically diagnosed with bladder cancer 
confirmed by transurethral resection of bladder tumor 
(TUR-BT). 
Cytologic samples were obtained from bladder washings 
in patients followed up for bladder cancer. In the case of 
hematuria patients, bladder washings were used when 
cystoscopy was carried out, and voided urine was used oth-
erwise; all tests were interpreted by an experienced 
pathologist. Qualitative assessment of NMP-22 was car-
ried out by using the NMP-22
Ⓡ BladderChek
Ⓡ test kit 
(Matritech, Newton, MA, USA).
NMP-22 testing was performed according to the recom-
mendations of the manufacturer. Drops of fresh urine were 
applied to the NMP-22 kit within 2 hours of collection, and 
results were read after 30 minutes. Tests showing a vertical 
line in both the control window and the test window were 
considered to be positive. A vertical line appearing in the 
control window indicated that the test was performed 
correctly.
Urine cytology and NMP-22 testing were carried out con-
currently in both groups. TUR was carried out when mass 
lesions were identified on cystoscopy, and cytology was re-
peated when no such lesion was observed.
The sensitivity, specificity, PPV, negative predictive val-
ue, and accuracy were calculated overall and for the screen-
ing and follow-up groups. The sensitivity of NMP-22 in as-
sessing specific stages and grades was compared with that 
of urine cytology. For statistical analysis, the authors used 
the chi-square test, Fisher’s exact test, and McNemar test 
run on SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA), and 
p-values less than 0.05 were considered to be indicative of 
statistical significance.
RESULTS
A total of 275 patients presented with atypical cells in urine 
cytology. Of these, 85 (30%) were diagnosed with bladder 
cancer according to pathology. Of the 275 patients, 96 test-
ed positive for NMP-22. Of these, 58 (60%) were diagnosed 
with bladder cancer, indicating a two-fold increase in PPV 
(p＜0.001) (Table 1). 
The 275 patients were divided into the hematuria 
screening group (143 patients) and the bladder cancer fol-
low-up group (132 patients) for analysis. Of the 143 pa-
tients in the screening group who also exhibited atypical 
urine cytology, 50 were diagnosed with bladder cancer. The 
PPV of atypical cells alone was 34.9%. Of the 132 patients 
in the follow-up group, 46 were diagnosed with bladder 
cancer. The PPV for atypical cytology alone in this group 
was 34.8%. No significant difference was observed in the 
cancer detection rates of the screening and follow-up 
groups (PPV) by use of atypical cytology (p=0.106). 
A total of 50 patients in the screening group tested pos-
itive for NMP-22; of these, 32 were diagnosed with bladder 
cancer, yielding a PPV of 64% (32/50). On the other hand, 
46 patients in the follow-up group tested positive for 
NMP-22; of these, 26 were diagnosed with bladder cancer, 
yielding a PPV of 56.5% (26/46) following stratification of 
subjects on the basis of NMP-22 test results. Comparison 
of the screening and follow-up groups showed no sig-
nificant difference in the cancer detection rate when Korean J Urol 2011;52:603-606
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TABLE 2. Sensitivity, specificity, PPV, NPV, and accuracy in 
patients with atypical cytology when indexed to NMP22 in the 
incident and prevalent group
Overall Screening Follow-up p-value
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
Accuracy (%)
68.2 
(58/85)
80.0 
(152/190)
60.4 
(58/96)
84.9 
(152/179)
76.2 
(210/275)
74.4 
(32/43)
82.0 
(82/100)
64.0 
(32/50)
88.1 
(82/93)
79.7 
(114/143)
61.9 
(26/42)
77.7 
(70/90)
56.5 
(26/46)
81.3 
(70/86)
72.7 
(96/132)
0.142
0.291
0.294
0.146
0.111
PPV: positive predictive value, NPV: negative predictive value, 
NMP-22: unclear matrix protein-22
TABLE 3. Sensitivity of atypical cytology indexed with NMP22 to
detect specific stages
Bladder cancer stage Overall
p-value
Ta-T2
Ta (%)
T1 (%)
T2 or higher (%)
Low grade (%)
High grade (%)
66.7 (28/42)
81.8 (27/33)
 90 (9/10)
58.1 (18/31)
87.0 (47/54)
0.165
0.002
NMP-22 testing was used (p=0.294) (Table 2); the cancer 
detection rates (PPV) of NMP-22 were 60.4% and 56.5%, 
respectively.
As also shown in Table 2, NMP-22 testing in subjects with 
atypical cytology had an overall sensitivity of 68.2% 
(58/85), specificity of 80% (152/190), PPV of 60.4% (58/96), 
negative predictive value of 84.9% (152/179), and accuracy 
of 76.2% (210/275). 
The sensitivity of NMP-22 with atypical cells was also 
analyzed after stratification on the basis of tumor stage and 
grade. For stratification on the basis of T stage, each subject 
was categorized as Ta, T1, or T2 or higher. For stratification 
on the basis of tumor grade, each case was categorized as 
low (grades 1 and 2) or high (grade 3). Stratification on the 
basis of T stage showed that sensitivity increased with T 
stage, yielding a sensitivity of 66.7% for Ta, 81.8% for T1, 
and 90% for T2 or higher stages; however, this increase was 
not statistically significant (p=0.165). On the other hand, 
the increase in sensitivity with increasing grade following 
grade-wise stratification was shown to be statistically sig-
nificant, with a sensitivity of 58.1% for low-grade tumors 
and of 87.0% for high-grade tumors (p=0.002) (Table 3).
DISCUSSION
The standard practice when encountering atypical urine 
cytology is to repeat the urine cytology or perform cysto-
scopy (in patients undergoing bladder cancer follow-up). 
Normal findings in these tests will most often result in over-
looking the finding of atypical urine cytology [4-6]. 
The sensitivity of urinary cytology in screening a sympto-
matic population is too low (30% to 50%) [7-9]. Even among 
patients undergoing treatment for bladder cancer and fol-
low-up, satisfactory results have not been obtained in regu-
lar cystoscopic examination or urine cytology. Hence, addi-
tional tests are needed.
NMP is present in low concentrations in the urine and 
in normal cells. However, in tumor cells, NMP levels are 
increased 80-fold. Thus, in cases of bladder cancer, NMP 
is excreted in the urine in high concentrations. The target 
antigen NMP-22 or the nuclear mitotic apparatus protein 
of the NMP-22 test is present within epithelial cells and 
during cell division [10-12]. The NMP-22 test used in our 
study is advantageous because the test can be performed 
immediately after the collection of urine from a patient in 
an outpatient clinic, allowing for rapid results to be ob-
tained and therefore helping to immediately determine the 
need for additional testing.
In the present study, of the 275 patients with atypical 
urine cytology, 85 were subsequently diagnosed with blad-
der cancer, yielding a relatively high cancer detection rate 
of 30.9% (85/275) for atypical cytology alone. Therefore, 
atypical findings in urine cytology should not be dismissed 
as normal. Atypical findings in bladder cancer can be due 
to necrotic cancer tissue, highly mitotic cancer, and the co-
existence of inflammation or hematuria. Findings of atyp-
ical urine cytology should thus be backed up with addi-
tional tests.
The NMP-22 test was carried out in the subjects of this 
study to augment the cancer detection rate in patients pre-
senting with atypical urine cytology. As shown in the re-
sults, NMP-22 testing used in combination with urine cy-
tology yielded a two-fold increase in the cancer detection 
rate (30.9% [85/275] to 60.4% [58/96]). These results were 
the same for both the screening and the follow-up groups.  
However, testing for NMP-22 in the presence of atypical 
urine cytology yielded a cancer detection rate of 60.4% 
(58/96), and 37 of the patients who tested negative for 
NMP-22 were subsequently diagnosed with bladder 
cancer. These points suggest that NMP-22 testing alone 
cannot fully complement urine cytology in the presence of 
atypical cytologic findings [13,14].
The findings of the present study show that the NMP-22 
test is noninvasive and easy to carry out, demonstrating its 
use as a tool for clinical examination in the presence of atyp-
ical urine cytology results [15-18].
Additionally, although statistical significance was not 
observed, the sensitivity of the NMP-22 assay increased 
with increasing T stage, and the sensitivity of the NMP-22 
assay was significantly higher for high-grade cancer than 
it was for low-grade cancer. Previous studies on NMP22 
have mostly examined the utility of NMP22 in diagnosis 
in hematuria patients and as follow-up tests in cases of Korean J Urol 2011;52:603-606
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bladder cancer. However, the present study differs from 
the other investigations in that it focused on the utility of 
the NMP22 assay in patients with atypical urine cytology. 
CONCLUSIONS
The present study examined the utility of the NMP22 assay 
in evaluating patients with atypical urine cytology. 
Although numerous studies have previously expounded on 
the utility of NMP22 assays in diagnosing bladder cancer, 
no study so far has assessed the utility of such assays in the 
evaluation of patients with atypical urine cytology. This 
study demonstrated that NMP22 assays help in diagnos-
ing bladder cancer in patients whose urine cytology was 
atypical.
On the other hand, this study could not enroll a sufficient 
number of subjects, which remains a crucial shortcoming. 
Furthermore, because only patients with atypical urine cy-
tology were examined, the proportion of patients with atyp-
ical cytology among those with hematuria or those being 
followed up for bladder cancer in whom urine cytology was 
carried out could not be assessed. Further in-depth studies 
thus appear necessary to address these limitations. 
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